TY - JOUR
T1 - Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition
AU - Flores, Omar
AU - Wang, Zhengying
AU - Knudsen, Karen E.
AU - Burnstein, Kerry L.
PY - 2010/3
Y1 - 2010/3
N2 - 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), inhibits proliferation of a variety of cell types including adenocarcinoma of the prostate. We have previously shown that 1,25-(OH)2D3 increases the stability of the cyclin-dependent kinase inhibitor p27 KIP1, decreases cyclin-dependent kinase 2 (CDK2) activity, and promotes G1 phase accumulation in human prostate cancer cells. These effects correlate with cytoplasmic relocalization of CDK2. In this study, we investigated the role of CDK2 cytoplasmic relocalization in the antiproliferative effects of 1,25-(OH)2D3. CDK2 was found to be necessary for prostate cancer cell proliferation. Although induced by 1,25-(OH)2D3, the cyclin-dependent kinase inhibitor p27KIP1 was dispensable for 1,25-(OH)2D 3-mediated growth inhibition. Reduction in CDK2 activity by 1,25-(OH)2D3 was associated with decreased T160 phosphorylation, a residue whose phosphorylation in the nucleus is essential for CDK2 activity. Ectopic expression of cyclin E was sufficient to overcome 1,25-(OH)2D3-mediated cytoplasmic mislocalization of CDK2 and all antiproliferative effects of 1,25-(OH)2D3, yet endogenous levels of cyclin E or binding to CDK2 were not affected by 1,25-(OH)2D3. Similarly, knockdown of the CDK2 substrate retinoblastoma, which causes cyclin E up-regulation, resulted in resistance to 1,25-(OH)2D3-mediated growth inhibition. Human prostate cancer cells resistant to growth inhibition by 1,25-(OH)2D 3 but retaining fully functional vitamin D receptors were developed.Thesecells didnotexhibit 1,25-(OH)2D3-mediated cytoplasmic relocalization of CDK2. Targeting CDK2 to the nucleus of 1,25-(OH)2D3-sensitive cancer cells blocked G1 accumulation and growth inhibition by 1,25-(OH)2D3. These data establish central roles for CDK2 nuclear-cytoplasmic trafficking and cyclin E in the mechanism of 1,25-(OH)2D3-mediated growth inhibition in prostate cancer cells.
AB - 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), inhibits proliferation of a variety of cell types including adenocarcinoma of the prostate. We have previously shown that 1,25-(OH)2D3 increases the stability of the cyclin-dependent kinase inhibitor p27 KIP1, decreases cyclin-dependent kinase 2 (CDK2) activity, and promotes G1 phase accumulation in human prostate cancer cells. These effects correlate with cytoplasmic relocalization of CDK2. In this study, we investigated the role of CDK2 cytoplasmic relocalization in the antiproliferative effects of 1,25-(OH)2D3. CDK2 was found to be necessary for prostate cancer cell proliferation. Although induced by 1,25-(OH)2D3, the cyclin-dependent kinase inhibitor p27KIP1 was dispensable for 1,25-(OH)2D 3-mediated growth inhibition. Reduction in CDK2 activity by 1,25-(OH)2D3 was associated with decreased T160 phosphorylation, a residue whose phosphorylation in the nucleus is essential for CDK2 activity. Ectopic expression of cyclin E was sufficient to overcome 1,25-(OH)2D3-mediated cytoplasmic mislocalization of CDK2 and all antiproliferative effects of 1,25-(OH)2D3, yet endogenous levels of cyclin E or binding to CDK2 were not affected by 1,25-(OH)2D3. Similarly, knockdown of the CDK2 substrate retinoblastoma, which causes cyclin E up-regulation, resulted in resistance to 1,25-(OH)2D3-mediated growth inhibition. Human prostate cancer cells resistant to growth inhibition by 1,25-(OH)2D 3 but retaining fully functional vitamin D receptors were developed.Thesecells didnotexhibit 1,25-(OH)2D3-mediated cytoplasmic relocalization of CDK2. Targeting CDK2 to the nucleus of 1,25-(OH)2D3-sensitive cancer cells blocked G1 accumulation and growth inhibition by 1,25-(OH)2D3. These data establish central roles for CDK2 nuclear-cytoplasmic trafficking and cyclin E in the mechanism of 1,25-(OH)2D3-mediated growth inhibition in prostate cancer cells.
UR - http://www.scopus.com/inward/record.url?scp=77149140115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77149140115&partnerID=8YFLogxK
U2 - 10.1210/en.2009-1116
DO - 10.1210/en.2009-1116
M3 - Article
C2 - 20147522
AN - SCOPUS:77149140115
VL - 151
SP - 896
EP - 908
JO - Endocrinology
JF - Endocrinology
SN - 0013-7227
IS - 3
ER -